logo

Recro Pharma Inc. (REPH)



Trade REPH now with
  Date
  Headline
4/16/2019 7:10:40 AM Recro Pharma Announces 6-Yr Extension Of License And Supply Deal Between Teva And Recro Gainesville
3/25/2019 7:14:50 AM Recro Pharma Appoints Arnaud Ajdler To Board
12/21/2018 7:04:09 AM Recro Pharma Amends IV Meloxicam License Agreement With Alkermes; Reduces 2019 Cash Requirements By $30 Mln
11/14/2018 7:07:20 AM Recro Pharma Announces Publication Of Phase II IV Meloxicam Abdominal Hysterectomy Data In Anesthesia & Analgesia
11/7/2018 7:23:00 AM Recro Pharma Q3 Net Loss $13.3 Mln Or $0.64/Shr Vs Loss Of $9.1 Mln Or $0.48/Shr Last Year
9/4/2018 7:04:56 AM Recro Pharma Provides Regulatory Update For IV Meloxicam
8/7/2018 7:13:48 AM Recro Pharma Q2 Net Loss $12.7 Mln Or $0.62/Shr
6/26/2018 7:08:00 AM Recro Pharma Reports Publication Of Phase III Clinical Data For IV Meloxicam For Pain Following Abdominoplasty Surgery
5/24/2018 7:04:24 AM Recro Pharma Receives Complete Response Letter From FDA Regarding NDA For IV Meloxicam
5/9/2018 7:23:35 AM Recro Pharma Q1 Net Loss $12.5 Mln Or $0.65/shr Vs Loss Of $8.1 Mln Or $0.42/Shr Last Year
4/30/2018 7:15:08 AM Recro Presents Data For Neuromuscular Blocking And Reversal Agents At The AUA 2018 Annual Meeting
3/27/2018 7:05:25 AM Recro Pharma Announces Publication Of Phase III IV Meloxicam Bunionectomy Data In The Clinical Journal Of Pain